 | • レポートコード：MRC2301B031 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、235ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に3,813.09百万ドルであった世界の計算生物学市場規模が、2022年に4,527.82百万ドルに達し、2027年には10,740.47百万ドルまで年平均18.83%で成長すると予測しています。当レポートは、計算生物学の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、サービス別（契約、自社開発）分析、用途別（細胞生物学的シミュレーション、臨床試験、創薬＆疾患モデリング、人体シミュレーションソフトウェア、前臨床医薬品開発）分析、エンドユーザー別（学術機関、商業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめております。なお、当書には、Agilent Technologies, Inc.、Applied Biological Materials, Inc.、BGI Group、Biomax Informatics AG、Chemical Computing Group Inc.、Compugen Ltd、Dassault Systemes、DNAnexus, Inc.、DNASTAR、Eurofins Scientific、Gene Network Sciences、Genedata AG、Genomatix、Illumina, Inc.、Insilico Biotechnology AG、Instemなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の計算生物学市場規模：サービス別 - 契約サービスの市場規模 - 自社開発サービスの市場規模 ・世界の計算生物学市場規模：用途別 - 細胞生物学的シミュレーションにおける市場規模 - 臨床試験における市場規模 - 創薬＆疾患モデリングにおける市場規模 - 人体シミュレーションソフトウェアにおける市場規模 - 前臨床医薬品開発における市場規模 ・世界の計算生物学市場規模：エンドユーザー別 - 学術機関における市場規模 - 商業における市場規模 ・世界の計算生物学市場規模：地域別 - 南北アメリカの計算生物学市場規模 アメリカの計算生物学市場規模 カナダの計算生物学市場規模 ブラジルの計算生物学市場規模 ... - アジア太平洋の計算生物学市場規模 日本の計算生物学市場規模 中国の計算生物学市場規模 インドの計算生物学市場規模 韓国の計算生物学市場規模 台湾の計算生物学市場規模 ... - ヨーロッパ/中東/アフリカの計算生物学市場規模 イギリスの計算生物学市場規模 ドイツの計算生物学市場規模 インドの計算生物学市場規模 フランスの計算生物学市場規模 ロシアの計算生物学市場規模 ... - その他地域の計算生物学市場規模 ・競争状況 ・企業情報 |
The Global Computational Biology Market size was estimated at USD 3,813.09 million in 2021 and expected to reach USD 4,527.82 million in 2022, and is projected to grow at a CAGR 18.83% to reach USD 10,740.47 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Computational Biology to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Services, the market was studied across Contract and In-house.
Based on Application, the market was studied across Cellular Biological Simulation, Clinical Trials, Drug Discovery & Disease Modelling, Human Body Simulation Software, and Preclinical Drug Development.
Based on End User, the market was studied across Academics and Commercial.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Computational Biology market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Computational Biology Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Computational Biology Market, including Agilent Technologies, Inc., Applied Biological Materials, Inc., BGI Group, Biomax Informatics AG, Chemical Computing Group Inc., Compugen Ltd, Dassault Systemes, DNAnexus, Inc., DNASTAR, Eurofins Scientific, Gene Network Sciences, Genedata AG, Genomatix, Illumina, Inc., Insilico Biotechnology AG, Instem, Luminex Corporation, Nimbus Discovery Llc, Partek, Inc., PerkinElmer, Inc., QIAGEN, Rosa & Co. Llc, Schrodinger, Simulation Plus Inc, SOPHiA GENETICS, Thermo Fisher Scientific, and Waters Corporation.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Computational Biology Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Computational Biology Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Computational Biology Market?
4. What is the competitive strategic window for opportunities in the Global Computational Biology Market?
5. What are the technology trends and regulatory frameworks in the Global Computational Biology Market?
6. What is the market share of the leading vendors in the Global Computational Biology Market?
7. What modes and strategic moves are considered suitable for entering the Global Computational Biology Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased Unmet Medical Needs and Rising Demand for Personalized Medicine
5.1.1.2. Expanding use of Computational Tools in Genomics, Epi-genomics, Proteomics, and Meta-genomics
5.1.1.3. Growing Bioinformatics Research and Growing Number of Clinical Studies
5.1.1.4. Adoption of Computational Biology in Oncology Therapeutics
5.1.2. Restraints
5.1.2.1. Dearth of Skilled Professionals to operate Computational Tools
5.1.3. Opportunities
5.1.3.1. Accelerating use of Bioinformatics and Multiscale Biological Modeling in Cell Modelling
5.1.3.2. Increased Funding in Bioinformatics coupled with Advancements in the Field of Computational Biology
5.1.3.3. Rising R&D for drug discovery
5.1.4. Challenges
5.1.4.1. Insufficiency of Interoperability and Multiplatform Capabilities and Lack of Well-Defined Standards and Common Data Formats for the Integration of Data
5.2. Cumulative Impact of COVID-19
6. Computational Biology Market, by Services
6.1. Introduction
6.2. Contract
6.3. In-house
7. Computational Biology Market, by Application
7.1. Introduction
7.2. Cellular Biological Simulation
7.3. Clinical Trials
7.4. Drug Discovery & Disease Modelling
7.5. Human Body Simulation Software
7.6. Preclinical Drug Development
8. Computational Biology Market, by End User
8.1. Introduction
8.2. Academics
8.3. Commercial
9. Americas Computational Biology Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Computational Biology Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Computational Biology Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Agilent Technologies, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Applied Biological Materials, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. BGI Group
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Biomax Informatics AG
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Chemical Computing Group Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Compugen Ltd
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Dassault Systemes
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. DNAnexus, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. DNASTAR
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Eurofins Scientific
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Gene Network Sciences
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Genedata AG
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Genomatix
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Illumina, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Insilico Biotechnology AG
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Instem
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Luminex Corporation
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Nimbus Discovery Llc
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Partek, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. PerkinElmer, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. QIAGEN
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Rosa & Co. Llc
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Schrodinger
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Simulation Plus Inc
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. SOPHiA GENETICS
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Thermo Fisher Scientific
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Waters Corporation
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing